Neurological Disease

MMB-4 is an oxime that can reactivate cholinesterases that have been inactivated by exposure to organophosphates such as Sarin or Soman.

Hemokinin 1, human TFA is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human TFA is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human TFA can produces an opioid-independent analgesia.

[DPro10] Dynorphin A (1-11), porcine hydrochloride, a N-Alkylated derivative, is a potent κ-opioid receptor agonist with a K_i value of 0.13 nM. [DPro10] Dynorphin A (1-11), porcine hydrochloride has analgesic property.

ONO-2921 is an orally active and selective N-type calcium channel blocker. ONO-2921 functionally blocks N-type calcium channels. ONO-2921 reduces paw withdrawal responses during persistent nociception and hyperalgesia to heat in neuropathic pain models. ONO-2921 can be used for research on neuropathic pain and nociceptive pain.

Dopamine D3 receptor antagonist-3 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist that can cross the blood-brain barrier. Dopamine D3 receptor antagonist-3 exhibits antagonist activity in the D3R-mediated β-arrestin recruitment assay with an IC₅₀ and a K_d of 2.5 μM and 0.49 μM. amine D3 receptor antagonist-3 is also an antagonist in the D3R-mediated Go-BRET assay with an IC₅₀ of 0.34 μM. Dopamine D3 receptor antagonist-3 can be used for the study of neuropsychiatric disorders, including substance use disorder.

Adiphenine is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC₅₀s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine has anticonvulsant effects.

(Rac)-LM11A-31 is a racemate of LM11A-31. LM11A-31 is a non-peptide modulator of p75NTR (neurotrophin receptor p75) and is an orally effective proNGF antagonist.

CMPPE is a GABAB receptor positive allosteric modulator (PAM) that inhibits alcohol self-administration and reinstatement behavior in rats.

(S)-Oxybutynin is a pharmaceutical intermediate. (S)-Oxybutynin can synthesize antifungal agents.

TRPM2-IN-2 is a potent and selective TRPM2 inhibitor (IC₅₀ = 0.66 μM) with minimal activity against TRPM8 and TRPV1 (IC₅₀ >10 μM). TRPM2-IN-2 exhibits robust neuroprotective effects in both in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model and in vivo transient middle cerebral artery occlusion (tMCAO) mouse model. TRPM2-IN-2 can be used for ischemic stroke research.

CB2 receptor agonist 4 (Compound 8) is a highly selective cannabinoid receptor type 2 (CB2 Receptor) agonist with an EC₅₀ of 13.99 nM. CB2 receptor agonist 4 shows no significant activity against cannabinoid receptor type 1. CB2 receptor agonist 4 can be used for the research of pain and immune-related diseases.

Neuropeptide Y (1-24) (human) is a neuropeptide with potencies in inhibiting the electricity stimulated twitch response of rat vas deferens. Neuropeptide Y (1-24) (human) stimulates N-methyl-D-aspartate (NMDA)-induced neuronal activation in the rat CA3 region of the dorsal hippocampus in vivo.

MOG (92-106), mouse, rat is a 15-peptide encephalitogenic epitope composed of amino acid residues 92-106 of myelin oligodendrocyte glycoprotein (MOG). MOG (92-106), mouse, rat serves as an I-A^s-restricted CD4⁺ T cell antigen. MOG (92-106), mouse, rat also induces extensive B cell responses against secondary myelin antigens such as MBP and PLP. MOG (92-106), mouse, rat is applicable to studies on multiple sclerosis, EAE, autoimmune demyelination, and antigen-specific T/B cell responses.

BPAM363 is an orally active, selective positive allosteric modulator (PAM) of AMPARs with blood-brain barrier penetration. BPAM363 selectively potentiates AMPAR activity in human and rat models, with an EC_2x value of 0.96 μM in rat embryonic cortex primary neurons. BPAM363 upregulates BDNF protein expression in rat primary cortical neuronal cultures. BPAM363 enhances AMPA-mediated excitatory postsynaptic responses in rat and mice. BPAM363 can be used for the study of cognitive disorders.

VBIT-3 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (K_d) of 31.3 μM. VBIT-3, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases.

Atalaphyllidine is a natural product. Atalaphyllidine can be isolated from the stem bark of Glycosmis chlorosperma. Atalaphyllidine inhibits DYRK1A kinase activity with an IC₅₀ of 2.2 μM. Atalaphyllidine can be used in the research of neurodegenerative diseases.

Ergtoxin-1 is a potassium channel blocker. Ergtoxin-1 is isolated from the venom of the Mexican scorpion Centruroides noxius. Ergtoxin 1 can block ERG-K⁺ channels in nerve, heart and endocrine cells.

TDO-IN-3 (compound 20) is an IDO1/TDO inhibitor with IC₅₀ values of 4.12 and 0.12 μM, respectively.

Icopezil (CP-118954) is an orally active, selective AchE inhibitor with an IC₅₀ of 0.33 nM. Icopezil increases acetylcholine levels in the brain and striatum of mammals, induces centrally mediated tremors and peripherally mediated salivation, and improves working memory performance in aged dogs. Icopezil serves as a parent compound for radioiodine-labeled acetylcholinesterase imaging agents. Icopezil is applicable to research related to Alzheimer's disease.

LY393615 (NCC1048) is a novel neuronal Ca²⁺ (calcium channel) and Na ⁺ channel (sodium channel) blocker with IC₅₀s of 1.9 μΜ and 5.2 μΜ for α1A and α1B calcium channel subunits. LY393615 has good brain penetration and neuroprotective effects in models of in cerebral ischemia that can be used for neurological disease research.